

SYNTHESIS OF (±)-ROEMECARINE AND (±)-EPIROEMECARINE:  
REVISED STEREOSTRUCTURE FOR (+)-ROEMECARINE

Osamu Hoshino<sup>a</sup>, Katsuhiko Itoh<sup>a</sup>, Bunsuke Umezawa<sup>a</sup>,  
Hiroyuki Akita<sup>b</sup>, and Takeshi Oishi<sup>b</sup>

Faculty of Pharmaceutical Sciences, Science University of Tokyo<sup>a</sup>,  
Shinjuku-ku, Tokyo 162, Japan and RIKEN<sup>b</sup> (the Institute of Physical  
and Chemical Research), Wako-shi, Saitama 351-01, Japan


**Abstract**— (±)-Roemecarine (1) and (±)-epiroemecarine (2) were synthesized from (±)-1,4-trans- and (±)-1,4-cis-4-acetoxy-1-benzyltetrahydroisoquinolin-6-ols (3 and 4). The present synthesis revealed that stereostructure of (+)-roemecarine was 1.

Recently, Shamma *et al.*<sup>1</sup> have reported that a new 4-hydroxy-1-benzyltetrahydroisoquinoline alkaloid, (+)-roemecarine, isolated from *Roemeria carica* A. Baytop (Papaveraceae) is 1,4-cis-4,6-dihydroxy-7-methoxy-1-(3',4'-dimethoxybenzyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline (2) on the basis of the <sup>1</sup>H-nmr spectral evidence. However, the relative stereochemistry of the 1-benzyl *vs.* 4-hydroxyl groups seemed to be ambiguous, because the *syn* relationship proposed for the alkaloid is solely based on that in 4-hydroxyaporphine, which essentially differs from 1-benzyltetrahydroisoquinoline in its conformational rigidity, and from a consideration of the <sup>1</sup>H-nmr spectra<sup>2</sup> of 3 and 4 the up-field shifted signal due to 8-H (δ5.76) observed in the alkaloid is rather suggestive of the *anti* relationship. In order to clarify the ambiguity, therefore, synthesis of (±)-1 and (±)-2 was required. We now wish to report the synthesis of (±)-1 and (±)-2 and the revised stereostructure (1) for (+)-roemecarine.

Hydrolysis of 4<sup>2</sup> in 5% methanolic KOH solution (r.t., 2.1 h) gave (±)-1,4-cis-4,6-diol (2)<sup>3,4</sup>. However, the <sup>1</sup>H-nmr spectral datum of (±)-2 was inconsistent with that of the alkaloid described in the literature<sup>1</sup>. On the other hand, a similar hydrolysis of 3<sup>2</sup> (r.t., 6 h) gave (±)-1,4-trans-4,6-diol (1)<sup>3-5</sup>, the <sup>1</sup>H-nmr spectral datum

of which was identical with that of the alkaloid described therein<sup>1,6</sup>.

Thus, it was proved that the stereostructure of (+)-roemecarine was 1,4-trans-4,6-dihydroxy-1-(3',4'-dimethoxybenzyl)-7-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline (1). Synthesis of the natural alkaloid is in progress.



	R <sup>1</sup>	R <sup>2</sup>
<u>1</u>	OH	H
<u>2</u>	H	OH
<u>3</u>	OAc	H
<u>4</u>	H	OAc

#### REFERENCES AND NOTES

1. T. Gözler, B. Gözler, N. Tanker, A. J. Freyer, H. Guinaudeau, and M. Shamma, *Heterocycles*, 1986, 24, 1227.
2. O. Hoshino, M. Ohtani, B. Umezawa, and Y. Iitaka, *Chem. Pharm. Bull.*, 1984, 32, 4872.
3. All new compounds noted in the text gave satisfactory elemental analyses.
4. (±)-Roemecarine (1); mp 115.5-117°C (C<sub>6</sub>H<sub>6</sub>-hexane) (87%). <sup>1</sup>H-nmrδ(400 MHz) (CDCl<sub>3</sub>): 2.69(3H, s, NCH<sub>3</sub>), 3.48(3H, s, 7-OCH<sub>3</sub>), 3.77, 3.86(each 3H, s, 2 x OCH<sub>3</sub>), 4.48(1H, t, J=2.8 Hz, 4-H), 5.73(1H, s, 8-H), 6.45(1H, d, J=1.9 Hz, 2'-H), 6.54(1H, dd, J=1.9, 8.1 Hz, 6'-H), 6.77(1H, d, J=8.1 Hz, 5'-H), 6.95(1H, s, 5-H). Ms m/z (%): 358(M-1)<sup>+</sup>(0.1), 315, 208(100), 190, 151.  
(±)-Epiroemecarine (2); mp 140-141.5°C (C<sub>6</sub>H<sub>6</sub>-hexane) (59%). <sup>1</sup>H-nmrδ(400 MHz) (CDCl<sub>3</sub>): 2.63(3H, s, NCH<sub>3</sub>), 3.64(3H, s, 7-OCH<sub>3</sub>), 3.80(6H, s, 2 x OCH<sub>3</sub>), 4.33(1H, br t, 4-H), 6.31(1H, d, J=2.0 Hz, 2'-H), 6.53(1H, s, 8-H), 6.54(1H, dd, J=2.0, 8.3 Hz, 6'-H), 6.70(1H, d, J=8.3 Hz, 5'-H), 6.81(1H, s, 5-H). Ms m/z (%): 358(M-1)<sup>+</sup>(0.1), 256, 208(100), 190, 151.
5. Acetylation with Ac<sub>2</sub>O-pyridine gave (±)-1,4-trans-4,6-diacetoxy-1-(3',4'-dimethoxybenzyl)-7-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline, <sup>1</sup>H-nmr spectrum of which was identical with that of an authentic sample<sup>2</sup>.
6. A direct comparison of each spectrum was not carried out, because we could not have the spectrum of the alkaloid.

Received, 8th May, 1987